PLURISTEM THERAPEUTICS INC. (NASDAQ:PSTI) Files An 8-K Submission of Matters to a Vote of Security Holders

ME Staff 8-k

8 years ago

PLURISTEM THERAPEUTICS INC. (NASDAQ:PSTI) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07. Submission of Matters to a Vote of Security Holders.

On May 25, 2017, Pluristem Therapeutics Inc. (the Company)
held its 2017 Annual Meeting of Stockholders (the 2017 Annual
Meeting). The results of the stockholder voting at the 2017
Annual Meeting are set forth below:

Proposal No. 1 Election of Directors

The stockholders elected the following individuals as directors
of the Company to hold office until the next annual meeting of
shareholders and until their successors shall have been duly
elected and qualified.

Director Name	For		Against		Abstain	Broker Non-Votes
Zami Aberman		22,799,652		1,987,332		188,268	19,435,840

Israel Ben-Yoram		23,607,522		575,814		791,916	19,435,840

Isaac Braun		23,615,503		571,645		788,104	19,435,840

Mark Germain		23,625,763		563,739		785,750	19,435,840

Moria Kwiat		22,899,597		1,855,606		220,049	19,435,840

Hava Meretzki		22,681,130		2,059,153		234,969	19,435,840

Nachum Rosman		24,159,423		574,496		241,333	19,435,840

Doron Shorrer		22,702,336		2,033,407		239,509	19,435,840

Yaky Yanay		22,848,791		1,994,757		131,704	19,435,840

Proposal No. 2 Advisory Vote on the Compensation of our Named
Executive Officers

For	Against	Abstain	Broker Non-Votes
18,941,992	5,696,599	336,661	19,435,840

Proposal No. 3 Ratification of the selection of Kost Forer Gabbay
Kasierer, a member of Ernst Young Global, as independent
registered public accounting firm of the Company for the fiscal
year ending June 30, 2017.

For	Against	Abstain	Broker Non-Votes
41,664,170	1,106,491	1,640,431	–

The results reported above are final voting results.

About PLURISTEM THERAPEUTICS INC. (NASDAQ:PSTI)
Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company’s products include PLX-PAD and PLX R18. The Company’s PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Company’s PLX products are administered using a standard needle and syringe. The Company’s PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women’s health diseases. PLURISTEM THERAPEUTICS INC. (NASDAQ:PSTI) Recent Trading Information
PLURISTEM THERAPEUTICS INC. (NASDAQ:PSTI) closed its last trading session up +0.02 at 1.40 with 157,186 shares trading hands.